Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

LIPAGG From biophysical chemistry to cell biology: Deciphering the role of lipids in the toxicity and spreading of protein aggregation

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€4.6m
Total cost
—
Partners
23 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227450

What the project is doing

In the project's own words, from its summary on CORDIS.

The LIPAGG project seeks to unravel the structural complexities of amyloid protein-lipid aggregates and investigate their role in pathological aggregation, cellular toxicity, and intercellular spread. Focusing on key human amyloid proteins—amylin (IAPP), amyloid beta (Aβ), and α-synuclein (αS)—linked to type 2 diabetes (T2D), Alzheimer's disease (AD), and Parkinson’s disease (PD), respectively, the project builds on recent discoveries made by the consortium.

These findings highlight the critical role of free lipids in membrane damage through the formation of stable lipid-amyloidogenic protein complexes, leading to the lipid-chaperone hypothesis. The project will explore unresolved mechanisms linking amyloid aggregation to cellular damage, focusing on three key aspects: 1) the toxicity of prefibrillar amyloid oligomers, 2) the interaction of amyloid proteins with lipid membranes, and 3) the pathological spread of amyloid aggregates in the brain.

Guided by the lipid-chaperone hypothesis, the consortium will train fifteen Doctoral Candidates (DCs), emphasizing the pivotal role of lipids in amyloid-related diseases. The training program will include cutting-edge methods in biophysics, peptide chemistry, molecular and structural biology, and cell biology. The scientific objectives of LIPAGG include characterizing amyloid-lipid complexes, understanding their impact on aggregation and membrane integrity, assessing their effects on cellular viability and intercellular spread, and developing chemical tools to block the formation of these complexes, offering potential therapeutic strategies.

The results will have significant societal impact, enhancing our understanding of AD, PD, and T2D, including potential improvements in diagnostic and therapeutic approaches. With support of a consortium of 23 partners from 8 countries, DCs will have access to state-of-the-art instrumentation, including 1.2 GHz NMR spectrometers, single-particle cryo-EM facilities, and supercomputers.

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator
Biosolveit GmbHSankt AugustinGermanyAssociatedpartner
Bruker Biospin GmbH & Co KgEttlingenGermanyAssociatedpartner
Forschungszentrum Julich GmbHJulichGermanyParticipant
Georg-August-Universitat Gottingen Stiftung Offentlichen RechtsGottingenGermanyAssociatedpartner
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyAssociatedpartner
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyParticipant
Schrodinger GmbHMannheimGermanyAssociatedpartner
H. Lundbeck ASValbyDenmarkAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
ParkinsonforeningenTaastrupDenmarkAssociatedpartner
Plasseraud IpParisFranceAssociatedpartner
Polypeptide Laboratories France SASStrasbourgFranceAssociatedpartner
Research PIECESPoitiersFranceAssociatedpartner
Universite De BordeauxBordeauxFranceAssociatedpartner
Universite Paris-SaclayGif-Sur-YvetteFranceParticipant
Biofordrug SRLTriggianoItalyAssociatedpartner
Universita Degli Studi Di CataniaCataniaItalyParticipant
Universita Della CalabriaArcavacata Di RendeItalyParticipant
Aminoverse B.V.NuthNetherlandsAssociatedpartner
Bioarctic ABStockholmSwedenAssociatedpartner
Probation Labs Sweden ABLundSwedenAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS